---
title: "Replimune Group GAAP EPS of -$0.79 misses by $0.07"
date: "2025-02-12 16:03:56"
summary: "Replimune Group press release (NASDAQ:REPL): Q3 GAAP EPS of -$0.79 misses by $0.07. As of December 31, 2024, cash, cash equivalents and short-term investments were $536.5 million, as compared to $420.7 million as of fiscal year ended March 31, 2024. The increase in cash balance was directly related to the..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Replimune Group [press release](https://seekingalpha.com/pr/19999690-replimune-reports-fiscal-third-quarter-2025-financial-results-and-provides-corporate-update) (NASDAQ:[REPL](https://seekingalpha.com/symbol/REPL "Replimune Group, Inc.")): Q3 GAAP EPS of -$0.79  misses by $0.07.
* As of December 31, 2024, cash, cash equivalents and short-term investments were $536.5 million, as compared to $420.7 million as of fiscal year ended March 31, 2024. The increase in cash balance was directly related to the public offering in November, somewhat offset by cash utilized in operating activities in advancing the Companyâ€™s clinical development plans.
* Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of December 31, 2024 will enable the Company to fund operations into the fourth quarter of 2026 which includes scale up for the potential commercialization of RP1 in skin cancers and for working capital and general corporate purposes and excludes any potential revenue.

[seekalpha](https://seekingalpha.com/news/4406775-replimune-group-gaap-eps-of-0_79-misses-by-0_07)
